Skip to Content
MilliporeSigma
All Photos(3)

Documents

SML0223

Sigma-Aldrich

Zoledronic acid monohydrate

≥98% (HPLC)

Synonym(s):

P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate, Zoledronate monohydrate, [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C5H10N2O7P2·H2O
CAS Number:
165800-06-6
Molecular Weight:
290.10
MDL number:
MFCD08448695
UNSPSC Code:
12352204
PubChem Substance ID:
329825242
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

color

white to beige

solubility

H2O: ≥2 mg/mL

storage temp.

2-8°C

SMILES string

O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2

InChI key

FUXFIVRTGHOMSO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Zoledronic acid monohydrate has been used:
  • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4
  • as a conjugate with D,L-lactide 75: glycolide 25 (PLGA) to analyze its bone formation functionality in distal femur
  • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells

Biochem/physiol Actions

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.

Preparation Note

This product is extremely unstable in solution and should be used shortly after reconstitution. If storage of the solution is necessary it can be held at 2-8ºC for no more than 24 hours.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Pamidronate, Disodium Salt A potent and specific inhibitor of bone resorption that does not cause any significant detrimental effect on bone growth and mineralization at concentrations used.

Sigma-Aldrich

506600

Pamidronate, Disodium Salt

GGTI 298 trifluoroacetate salt hydrate ≥90% (HPLC), film

Sigma-Aldrich

G5169

GGTI 298 trifluoroacetate salt hydrate

Etidronate disodium hydrate ≥97% (NMR), solid

Sigma-Aldrich

P5248

Etidronate disodium hydrate

USP

USP

1492801

Pamidronate disodium

Alendronate, Sodium Salt An amino-bisphosphonate that acts as a potent inhibitor of bone resorption and cartilage destruction.

Sigma-Aldrich

126855

Alendronate, Sodium Salt

vibrant-m

Y0000524

Pamidronate disodium pentahydrate

Risedronate sodium 2.5-hydrate European Pharmacopoeia (EP) Reference Standard

Y0001541

Risedronate sodium 2.5-hydrate

Neridronate ≥97% (NMR), solid

Sigma-Aldrich

N6037

Neridronate

Tiludronate disodium salt hydrate ≥98% (HPLC)

Sigma-Aldrich

T4580

Tiludronate disodium salt hydrate

Xu Li et al.
International journal of pharmaceutics, 526(1-2), 69-76 (2017-04-30)
Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce
Xu Li et al.
ACS applied materials & interfaces, 11(7), 7311-7319 (2019-01-29)
Bisphosphonates are generally used to treat bone diseases, such as bone metastasis from cancer. There is evidence that, through the modification of the pharmacokinetics and biodistribution of bisphosphonates by formulating them into nanoparticles, they may be able to treat extraskeletal
Kiichi Yamamoto et al.
Parasitology international, 66(2), 89-99 (2016-12-07)
Recent evidence suggests that 1α,25-dihydroxyvitamin D3 (calcitriol, VD3), the active form of vitamin D (VD), can inhibit the proliferation of microorganisms. In the present study, we conducted in vitro experiments and utilized in vivo murine models to investigate the antimalarial
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Akoury E, et al.
Cancer Cell International, 19(1), 28-28 (2019)
Controlled delivery of zoledronate improved bone formation locally in vivo
Gou W, et al.
PLoS ONE, 9(3), e91317-e91317 (2014)
View All Related Papers

Related Content

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service